KRAS and neoplasm: Polymerase Chain Reaction (PCR—EasyPGX ready KRAS, Diatech Pharmacogenetics, Jesi, Italy) revealed a KRAS c.34G > T p.G12C mutation while immunohistochemistry (IHC—antibody 22C3 pharmDx, Dako, Santa Clara) for Programmed Death Ligand 1 (PD-L1) tested positive in 5% of tumor cells.